Ascent Wealth Partners LLC Purchases New Shares in Edwards Lifesciences Co. (NYSE:EW)

Ascent Wealth Partners LLC purchased a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,546 shares of the medical research company’s stock, valued at approximately $263,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Alpha Financial Partners LLC acquired a new stake in Edwards Lifesciences during the third quarter worth about $693,000. Eastern Bank acquired a new stake in Edwards Lifesciences during the third quarter worth about $98,000. International Assets Investment Management LLC grew its stake in Edwards Lifesciences by 10,990.6% during the third quarter. International Assets Investment Management LLC now owns 163,919 shares of the medical research company’s stock worth $10,817,000 after buying an additional 162,441 shares in the last quarter. Mount Yale Investment Advisors LLC grew its stake in Edwards Lifesciences by 41.0% during the third quarter. Mount Yale Investment Advisors LLC now owns 8,401 shares of the medical research company’s stock worth $554,000 after buying an additional 2,441 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC grew its stake in Edwards Lifesciences by 8.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 21,649 shares of the medical research company’s stock worth $1,429,000 after buying an additional 1,615 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on EW. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, Truist Financial reissued a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $79.95.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,489 shares of company stock valued at $2,002,829. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $73.25 on Friday. The company has a market capitalization of $43.20 billion, a PE ratio of 10.51, a P/E/G ratio of 4.82 and a beta of 1.10. The company has a 50 day simple moving average of $72.85 and a two-hundred day simple moving average of $70.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.